(+/-)-16-hydroxy-15-deoxy-16-methylprostaglandin E1 methyl ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (+/-)-16-hydroxy-15-deoxy-16-methylprostaglandin E1 methyl ester
• 英文别名: E1-misoprostol；methyl 7-[3(R)-hydroxy-2β-(4(RS)-4-hydroxy-4-methyl-trans-1-octenyl)-5-oxocyclopentane]-1α-heptanoate；methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate；methyl 7-[3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate
• 化学式: C₂₂H₃₈O₅
• 分子量: 382.541
• InChiKey: OJLOPKGSLYJEMD-ZRDIBKRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-羟基-5-羰基-1-环戊烯-1-庚酸甲酯 在 甲基锂 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 2.08h， 生成 (+/-)-16-hydroxy-15-deoxy-16-methylprostaglandin E1 methyl ester
  参考文献：
  名称：

  Prostanoids. Part LXXIV. Antiulcerous activity of misoprostol and its 11-deoxy analog. Misoprostol synthesis

  摘要：

  DOI：

  10.1007/bf02465826

文献信息

• PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY
  申请人：Andersson Martin

  公开号：US20120065179A1

  公开（公告）日：2012-03-15

  There is provided a prodrug of a pharmaceutically active agent, such prodrug comprising a beta-keto carboxylic acid, a beta-keto carboxylic acid salt or a beta-keto carboxylic acid ester functional group, a pharmaceutical composition comprising the prodrug, and to the use of the prodrug or composition for treatment of a mammalian subject suffering from a condition which can be cured or alleviated by administration of the pharmaceutically active agent. There is further provided a method of inhibiting decarboxylation of a compound comprising a beta-keto carboxylic acid or a salt thereof with a monovalent cation, characterized in that a dry salt of the beta-keto carboxylic acid with a divalent or polyvalent cation is prepared.

  提供了一种药物活性成分的前药，该前药包括β-酮羧酸、β-酮羧酸盐或β-酮羧酸酯官能团；以及包含该前药的制药组合物，以及将该前药或组合物用于治疗哺乳动物患有可通过药物活性成分的给药治愈或缓解的疾病的用途。还提供了一种抑制含有单价阳离子的β-酮羧酸化合物或其盐的脱羧反应的方法，其特征在于制备出与二价或多价阳离子形成的β-酮羧酸干盐。
• Blister pack of mifepristone and misoprostol
  申请人：Exelgyn

  公开号：EP1941886A1

  公开（公告）日：2008-07-09

  The invention provides an article of manufacture comprising (i) a packaging material and (ii) a pharmaceutical composition containing a safe and therapeutically effective amount of mifepristone or a pharmaceutically acceptable derivative thereof, and (iii) a safe and therapeutically effective amount of misopristol or a pharmaceutically acceptable derivative thereof.

  本发明提供了一种制成品，它包含（i）包装材料和（ii）药物组合物，其中含有安全且治疗有效量的米非司酮或其药学上可接受的衍生物，以及（iii）安全且治疗有效量的米索司托或其药学上可接受的衍生物。
• PHARMACEUTICAL FORMULATION FOR PARENTERAL ADMINISTRATION
  申请人：Currie Mark G.

  公开号：US20100010046A1

  公开（公告）日：2010-01-14

  Parenteral formulations comprising ketorolac, and a compound of formula II wherein R is hydrogen or lower alkyl. Such formulations are used for the treatment and prevention of pain.
• Prostanoids. Part LXXIV. Antiulcerous activity of misoprostol and its 11-deoxy analog. Misoprostol synthesis
  作者：N. A. Ivanova、O. M. Kuznetsov、A. M. Shainurova、F. A. Akbutina、I. N. Gaisina、R. R. Akhmetvaleev、F. A. Zarudii、V. A. Davydova、T. A. Sapozhnikova、M. S. Miftakhov

  DOI：10.1007/bf02465826

  日期：1998.11